Cargando…
664. LiaX as a Surrogate Marker of Daptomycin Susceptibility in Multidrug-Resistant Enterococcus faecium Recovered from Cancer Patients
BACKGROUND: Vancomycin-resistant Enterococcus faecium (VREfm) are leading causes of bloodstream infections (BSI) in patients (pts) with hematological malignancies (HM). Daptomycin (DAP) is commonly used to treat VRE BSI, but DAP non-susceptibility (DAP-NS) in pts with HM is increasing. Current metho...
Autores principales: | Axell-House, Dierdre B, Khan, Ayesha, Shamoo, Yousif, Shelburne, Samuel A, Tran, Truc T, Arias, Cesar A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777827/ http://dx.doi.org/10.1093/ofid/ofaa439.857 |
Ejemplares similares
-
2350. LiaF is required for LiaX mediated protection against Daptomycin and LL-37 in Enterococcus faecalis OG1RF
por: Botero, Diana Panesso, et al.
Publicado: (2022) -
599. LiaF is an Activator of the LiaR-Mediated Response Against Daptomycin and Antimicrobial Peptides in Multidrug-Resistant Enterococcus faecalis (Efs)
por: Ortiz-Velez, Laura C, et al.
Publicado: (2019) -
The LiaFSR-LiaX System Mediates Resistance of Enterococcus faecium to Peptide Antibiotics and to Aureocin A53- and Enterocin L50-Like Bacteriocins
por: Tymoszewska, Aleksandra, et al.
Publicado: (2023) -
1399. Efficacy of Daptomycin Combination with β-Lactams for Daptomycin-resistant Enterococcus faecium Harboring LiaSR Substitutions
por: Kebriaei, Razieh, et al.
Publicado: (2018) -
602. Mechanism of LiaY-Mediated Daptomycin Resistance in Enterococcus faecalis
por: Nguyen, April, et al.
Publicado: (2019)